NCT02981069View on ClinicalTrials.gov

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

July 14, 2022

Study Completion Date

March 19, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin

10mg

DRUG

Exenatide

Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)

DRUG

Placebo

Placebo for Dapagliflozin

Trial Locations (1)

78229

University of Texas Health Science Center, San Antonio

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER